An interventional study of structured nano-water and Hydrochlorothiazide (HCTZ) in Renal Stones and Idiopathic Hypercalciuria, sponsored by ALI KAMAL M. SAMI. Completed at 1 site in Iraq. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-11-08.
Sponsored by ALI KAMAL M. SAMI · Not applicable, Interventional, and Prevention
We assessed the effect of structured nano-water in the prevention of recurrent stone formation in patients with recurrent calcium oxalate stones and hypercalciuria.
The majority of stones (85%) contain primarily calcium oxalate. Most renal stones are idiopathic calcium stones, and the most common predisposing factor in these patients is hypercalciuria. Structured nano-water is a new type of water that has been prepared using different types of energy fields electromagnetic fields to produce this structured nano- water that has new and different characteristics from the ordinary water.
In this study, we compared the efficacy of the nano- water with hydrochlorothiazide and with ordinary bottled drinking water in the prevention of recurrent renal stones in patients with idiopathic hypercalciuria.
We conducted a three-year randomized trial comparing the effect of structured water with the effect of hydrochlorothiazide and ordinary bottled water in 325 patients with recurrent calcium oxalate stones and hypercalciuria.
The patients were randomly divided into three groups. Group A included 108 patients who used structured nano-water in a dose of 20 mL/kg as a daily dose.
Group B of 107 patients used 50 mg hydrochlorothiazide tablets as a daily dose, and group C consisted of another 110 patients used ordinary drinking bottled water in a daily dose of 20 mL/kg .
The assessments were done by urine analysis with renal ultrasonography and radiology ( Kidney Ureter Bladder KUB X-rays) were done at baseline, at yearly intervals, also at any time of recurrence, and at the end of the 3 years (36th month).
The patients, care providers, and the investigators were blinded about the type of water used since the water bottles were unlabeled when given to the patients.
All patients were informed and signed a written informed consent form.
324 studies on the registry are indexed under Nephrolithiasis; 90 are open to participants now.
This study's enrollment of 325 is above the median of 92 across 257 interventional studies indexed under Nephrolithiasis.
Browse Nephrolithiasis studies →ALI KAMAL M. SAMI is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients receiving nano-water in a daily dose of 20 mL/Kg
Dietary Supplement: structured nano-water
Patients receiving Hydrochlorothiazide in a daily dose of 50 mg.
Drug: Hydrochlorothiazide (HCTZ)
Patients receiving ordinary bottled drinking water in a daily dose of 20 mL/Kg
Other: ordinary bottled drinking water
Hydrochlorothiazide is a drug used to prevent recurrent renal stone formation in patients with idiopathic hypercalciuria
hydrochlorothiazide is a drug used to prevent recurrent stone formation i patients with idiopathic hypercalciuria
Patients with idiopathic hypercalciuria receiving regular bottled drinking water as a placebo to see its effect.
Recurrent renal stones
recurrent renal stone were diagnosed by ultrasound and X-ray ( kidney ureter Bladder X-ray)
Time frame: From enrollment to the end of treatment at 36 months
Plan to share: No — Patients agreed to participate in this clinical trial based on keeping confidentiality about their personal informations
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ALI KAMAL M. SAMI